Preclinical evaluation of biomarkers for response monitoring to the MET inhibitor BAY-853474

References

• Athauda G, Giubellino A, Coleman JA, Horak C, Steeg PS, Lee MJ, Trepel J, Wimberly J, Sun J, Coxon A, Burgess TL, Bottaro DP. (2006). c-Met ectodomain shedding rate correlates with malignant potential. Clin Cancer Res 12:4154–4162.
   Google Scholar
• Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. (2003). Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915–925.
   PubMed Web of Science ®Google Scholar
• Blume-Jensen P, Hunter T. (2001). Oncogenic kinase signalling. Nature 411:355–365.
   PubMed Web of Science ®Google Scholar
• Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, Aaronson SA. (1991). Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251:802–804.
   PubMed Web of Science ®Google Scholar
• Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Olivero M, Naldini L, Gaudino G, Tamagnone L, Coffer A, Comoglio PM. (1992). Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 119:629–641.
   PubMed Web of Science ®Google Scholar
• Cecchi F, Rabe DC, Bottaro DP. (2010). Targeting the HGF/Met signalling pathway in cancer. Eur J Cancer 46:1260–1270.
   PubMed Web of Science ®Google Scholar
• Christensen JG, Burrows J, Salgia R. (2005). c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 225:1–26.
   PubMed Web of Science ®Google Scholar
• Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR, Yamazaki S, Alton GR, Mroczkowski B, Los G.. (2007). Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 6:3314–3322.
   PubMed Web of Science ®Google Scholar
• Comoglio PM, Giordano S, Trusolino L. (2008). Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 7:504–516.
   PubMed Web of Science ®Google Scholar
• Cooper CS, Park M, Blair DG, Tainsky MA, Huebner K, Croce CM, Vande Woude GF. (1984). Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 311:29–33.
   PubMed Web of Science ®Google Scholar
• Dean M, Park M, Le Beau MM, Robins TS, Diaz MO, Rowley JD, Blair DG, Vande Woude GF. (1985). The human met oncogene is related to the tyrosine kinase oncogenes. Nature 318:385–388.
   PubMed Web of Science ®Google Scholar
• Di Renzo MF, Narsimhan RP, Olivero M, Bretti S, Giordano S, Medico E, Gaglia P, Zara P, Comoglio PM. (1991). Expression of the Met/HGF receptor in normal and neoplastic human tissues. Oncogene 6:1997–2003.
   PubMed Web of Science ®Google Scholar
• Dong G, Chen Z, Li ZY, Yeh NT, Bancroft CC, Van Waes C. (2001). Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma. Cancer Res 61:5911–5918.
   PubMed Web of Science ®Google Scholar
• Eder JP, Shapiro GI, Appleman LJ, Zhu AX, Miles D, Keer H, Cancilla B, Chu F, Hitchcock-Bryan S, Sherman L, McCallum S, Heath EI, Boerner SA, LoRusso PM. (2010). A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res 16:3507–3516.
   PubMed Web of Science ®Google Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jänne PA. (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039–1043.
   PubMed Web of Science ®Google Scholar
• Furge KA, Zhang YW, Vande Woude GF. (2000). Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene 19:5582–5589.
   PubMed Web of Science ®Google Scholar
• Galvani AP, Cristiani C, Carpinelli P, Landonio A, Bertolero F. (1995). Suramin modulates cellular levels of hepatocyte growth factor receptor by inducing shedding of a soluble form. Biochem Pharmacol 50:959–966.
   PubMed Web of Science ®Google Scholar
• Ghoussoub RA, Dillon DA, D’Aquila T, Rimm EB, Fearon ER, Rimm DL. (1998). Expression of c-met is a strong independent prognostic factor in breast carcinoma. Cancer 82:1513–1520.
   PubMed Web of Science ®Google Scholar
• Gordon MS, Sweeney CS, Mendelson DS, Eckhardt SG, Anderson A, Beaupre DM, Branstetter D, Burgess TL, Coxon A, Deng H, Kaplan-Lefko P, Leitch IM, Oliner KS, Yan L, Zhu M, Gore L. (2010). Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors. Clin Cancer Res 16:699–710.
   PubMed Web of Science ®Google Scholar
• Grant DS, Kleinman HK, Goldberg ID, Bhargava MM, Nickoloff BJ, Kinsella JL, Polverini P, Rosen EM. (1993). Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci USA 90:1937–1941.
   PubMed Web of Science ®Google Scholar
• Hammerman PS, Jänne PA, Johnson BE. (2009). Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. Clin Cancer Res 15:7502–7509.
   PubMed Web of Science ®Google Scholar
• Houldsworth J, Cordon-Cardo C, Ladanyi M, Kelsen DP, Chaganti RS. (1990). Gene amplification in gastric and esophageal adenocarcinomas. Cancer Res 50:6417–6422.
   PubMed Web of Science ®Google Scholar
• Jin H, Yang R, Zheng Z, Romero M, Ross J, Bou-Reslan H, Carano RA, Kasman I, Mai E, Young J, Zha J, Zhang Z, Ross S, Schwall R, Colbern G, Merchant M. (2008). MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res 68:4360–4368.
   PubMed Web of Science ®Google Scholar
• Kim ES, Herbst RS, Lee JJ, Blumenschein G, Tsao A, Wistuba I, Alden C, Gupta S, Stewart D, Hong WK.. (2009). Phase II randomized study of biomarker-directed treatment for non-small cell lung cancer (NSCLC): The BATTLE (Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination) clinical trial program. J Clin Oncol 27: 15s (suppl; abstr 8024).
   Google Scholar
• Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ. (2010). Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693–1703.
   PubMed Web of Science ®Google Scholar
• Liu X, Newton RC, Scherle PA. (2010). Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends Mol Med 16:37–45.
   PubMed Web of Science ®Google Scholar
• Nath D, Williamson NJ, Jarvis R, Murphy G. (2001). Shedding of c-Met is regulated by crosstalk between a G-protein coupled receptor and the EGF receptor and is mediated by a TIMP-3 sensitive metalloproteinase. J Cell Sci 114:1213–1220.
   PubMed Web of Science ®Google Scholar
• O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ; IRIS Investigators. (2003). Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994–1004.
   PubMed Web of Science ®Google Scholar
• Peschard P, Park M. (2007). From Tpr-Met to Met, tumorigenesis and tubes. Oncogene 26:1276–1285.
   PubMed Web of Science ®Google Scholar
• Sampson ER, Martin BA, Morris AE, Xie C, Schwarz EM, O’Keefe RJ, Rosier RN. (2011). The orally bioavailable met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model. J Bone Miner Res 26:1283–1294.
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L; National Cancer Institute of Canada Clinical Trials Group. (2005). Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792.
   PubMed Web of Science ®Google Scholar
• Schlessinger J. (2000). Cell signaling by receptor tyrosine kinases. Cell 103:211–225.
   PubMed Web of Science ®Google Scholar
• Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M, Allikmets R, Chidambaram A, Bergerheim UR, Feltis JT, Casadevall C, Zamarron A, Bernues M, Richard S, Lips CJ, Walther MM, Tsui LC, Geil L, Orcutt ML, Stackhouse T, Lipan J, Slife L, Brauch H, Decker J, Niehans G, Hughson MD, Moch H, Storkel S, Lerman MI, Linehan WM, Zbar B. (1997). Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16:68–73.
   PubMed Web of Science ®Google Scholar
• Soman NR, Correa P, Ruiz BA, Wogan GN. (1991). The TPR-MET oncogenic rearrangement is present and expressed in human gastric carcinoma and precursor lesions. Proc Natl Acad Sci USA 88:4892–4896.
   PubMed Web of Science ®Google Scholar
• Tseng JR, Kang KW, Dandekar M, Yaghoubi S, Lee JH, Christensen JG, Muir S, Vincent PW, Michaud NR, Gambhir SS. (2008). Preclinical efficacy of the c-Met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by 18F-FDG small-animal PET. J Nucl Med 49:129–134.
   PubMed Web of Science ®Google Scholar
• Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, Issels R, van Oosterom A, Hogendoorn PC, Van Glabbeke M, Bertulli R, Judson I. (2004). Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364:1127–1134.
   PubMed Web of Science ®Google Scholar
• Wen PY, Schiff D, Cloughesy TF, Raizer JJ, Laterra J, Smitt M, Wolf M, Oliner KS, Anderson A, Zhu M, Loh E, Reardon DA. (2011). A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro-oncology 13:437–446.
   PubMed Web of Science ®Google Scholar
• Wiehr S, von Ahsen O, Röse L, Mannheim JG, Honndorf V, Kukuk D, Reischl G, Pichler BJ. (2012). Preclinical evaluation of the c-Met inhibitor BAY-853474 in a gastric cancer xenograft model using small animal PET. Manuscript submitted.
   Google Scholar
• Yap TA, Olmos D, Brunetto AT, Tunariu N, Barriuso J, Riisnaes R, Pope L, Clark J, Futreal A, Germuska M, Collins D, deSouza NM, Leach MO, Savage RE, Waghorne C, Chai F, Garmey E, Schwartz B, Kaye SB, de Bono JS. (2011). Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol 29:1271–1279.
   PubMed Web of Science ®Google Scholar
• Yu J, Miehlke S, Ebert MP, Hoffmann J, Breidert M, Alpen B, Starzynska T, Stolte Prof M, Malfertheiner P, Bayerdörffer E. (2000). Frequency of TPR-MET rearrangement in patients with gastric carcinoma and in first-degree relatives. Cancer 88:1801–1806.
   Google Scholar
• Zhang YW, Su Y, Volpert OV, Vande Woude GF. (2003). Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci USA 100:12718–12723.
   PubMed Web of Science ®Google Scholar
• Zhang YW, Vande Woude GF. (2003). HGF/SF-met signaling in the control of branching morphogenesis and invasion. J Cell Biochem 88:408–417.
   PubMed Web of Science ®Google Scholar